Lipohypertrophy remains a frequent complication of insulin therapy, reportedly in 28.7% of those with type 1 diabetes and 3.6% with type 2 diabetes with a greater tendency of developing the lesion in patients using medium or long-acting insulin [32, 33]. The gene discussed is INS; the disease is type 2 diabetes mellitus.